Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences, Inc. (Nasdaq: KZR) is a clinical-stage biotechnology company dedicated to discovering and developing novel small molecule therapeutics to address unmet medical needs in autoimmunity and cancer. Founded in 2015 and headquartered in South San Francisco, California, Kezar focuses on creating therapies that can significantly improve patient outcomes.
The company's lead product candidate, Zetomipzomib (KZR-616), is a selective immunoproteasome inhibitor currently under clinical investigation. Zetomipzomib is being tested in Phase 2 trials for five autoimmune diseases, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis. In addition, Phase 1b/2 trials are underway for systemic lupus erythematosus and lupus nephritis, making it a promising candidate for treating multiple chronic immune-mediated diseases.
Kezar's preclinical pipeline also includes another selective immunoproteasome inhibitor, tentatively named KZR-TBD, aimed at treating oncology and autoimmune conditions. These efforts highlight Kezar's commitment to exploring innovative solutions for complex diseases.
Recently, Kezar Life Sciences has achieved significant milestones. Notably, in collaboration with Everest Medicines, the company received approval from China's National Medical Products Administration (NMPA) for the investigational new drug (IND) application for the Phase 2b PALIZADE trial of zetomipzomib in patients with lupus nephritis. This global, placebo-controlled trial will evaluate the efficacy and safety of zetomipzomib, marking Kezar's expansion into the Asian market.
Financially, Kezar Life Sciences continues to secure partnerships and funding to support its ambitious research and development goals. The company's strategic collaborations, like the one with Everest Medicines, enhance its ability to reach more patients and broaden its geographical footprint.
For more information, visit the company's official website at www.kezarlifesciences.com.
Kezar Life Sciences, Inc. (Nasdaq: KZR) has appointed Dr. Micki Klearman to its Board of Directors. Dr. Klearman, who brings over a decade of biopharmaceutical expertise, has significantly advanced treatments for autoimmune diseases such as rheumatoid arthritis and Giant Cell Arteritis during her tenure at Genentech/Roche. Her addition is expected to enhance Kezar's strategic direction as the company focuses on developing innovative therapies for immune-mediated diseases. This leadership change aims to leverage Dr. Klearman's experience to drive the company's research and clinical programs forward.
Kezar Life Sciences, a clinical-stage biotechnology firm focusing on immune-mediated and oncologic disorders, announced that CEO John Fowler will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 2:00 p.m. ET. The chat will be accessible via live webcast on the company's website, with a replay available for 90 days post-event. Kezar is developing innovative therapies, including KZR-616 for lupus nephritis and KZR-261, targeting cancer treatment.
Kezar Life Sciences (Nasdaq: KZR) will present a MISSION Phase 1b data update on June 2, 2021, at 4:30 p.m. ET during EULAR 2021. This event will showcase final data from a 25-week study assessing the safety and tolerability of KZR-616 in 47 patients with systemic lupus erythematosus. KZR-616, a first-in-class selective immunoproteasome inhibitor, has shown a favorable safety profile in earlier trials and is being evaluated for severe autoimmune diseases, with ongoing Phase 2 trials in lupus nephritis and other conditions.
Kezar Life Sciences (Nasdaq: KZR) announced its Q1 2021 financial results, reporting a net loss of $13 million, or $0.25 per share. Cash, cash equivalents, and marketable securities totaled $142.3 million. R&D expenses increased to $9.3 million, driven by the KZR-616 program. The company is advancing two clinical trials: MISSION for SLE and lupus nephritis, and PRESIDIO for dermatomyositis and polymyositis. KZR-261, a new protein secretion inhibitor, is on track for an IND submission by mid-2021. Interim data is expected later this year, showcasing ongoing development and commitment to growth.
Kezar Life Sciences presented preclinical data on its protein secretion program at the AACR 2021 Virtual Annual Meeting. The analysis focused on KZR-261, a small molecule inhibitor targeting the Sec61 translocon, which may offer novel therapies for various tumor indications. Preliminary findings suggest that KZR-261 shows sensitivity in certain tumor types while sparing normal cells. An IND application is expected by mid-2021, paving the way for a Phase 1 trial assessing its safety and anti-tumor activity in solid tumors.
Kezar Life Sciences, Inc. (KZR) reported its financial results for Q4 and full year 2020, highlighting advances in its clinical programs despite challenges. The company’s lead candidate, KZR-616, is progressing in multiple trials, with FDA orphan drug designations granted for specific conditions. Financially, cash and equivalents rose to $140.4 million, while R&D expenses increased due to ongoing clinical trials, leading to a Q4 net loss of $10.9 million. Looking ahead, the company anticipates interim data from its key studies in 2021, supporting its strategic development goals.
Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotechnology company, announced CEO John Fowler's participation in the “Autoimmune/Complement” panel at the Cowen 41st Annual Virtual Health Care Conference on March 3, 2021, at 11:40 AM EST. The event will be live for conference attendees. Kezar focuses on developing first-in-class therapies for rare autoimmune diseases and cancer, with lead candidate KZR-616 in Phase 2 trials for lupus nephritis and other conditions. KZR-261 is in IND-enabling activities targeting cancer.
Kezar Life Sciences (Nasdaq: KZR) announced that CEO John Fowler will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be available on demand starting February 16 on their website. Additionally, Chief Scientific Officer Chris Kirk, Ph.D., will join a panel on drugging undruggable cancer targets. Kezar specializes in developing innovative treatments for immune-mediated and oncologic disorders, with lead candidate KZR-616 in Phase 2 trials for lupus nephritis, dermatomyositis, and polymyositis.
Kezar Life Sciences, a clinical-stage biotechnology company, announced that CEO John Fowler will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be available on January 11, 2021, at 6:00 am EST on the company’s website. Kezar is focused on developing breakthrough treatments for immune-mediated and oncologic disorders, including KZR-616, a first-in-class immunoproteasome inhibitor, and KZR-261 for cancer treatment. An archived replay will be accessible for 90 days post-conference.
FAQ
What is the current stock price of Kezar Life Sciences (KZR)?
What is the market cap of Kezar Life Sciences (KZR)?
What is Kezar Life Sciences focused on?
What is Zetomipzomib (KZR-616)?
What clinical trials are currently underway for Zetomipzomib?
Where is Kezar Life Sciences headquartered?
What significant recent achievements has Kezar Life Sciences made?
What are Kezar's preclinical products?
When was Kezar Life Sciences founded?
Who is Kezar Life Sciences' regional partner in Asia?
How can I get more information about Kezar Life Sciences?
What is the PALIZADE trial?
